Life Sciences

Gene-Edited Food Is Coming, but Will Shoppers Buy?

Associated Press | |

A new generation of biotech foods is getting close to the grocery aisles.

Genentech Gets FDA Priority Review Designation for Combination Treatment of Triple-Negative Breast Cancer

Edward Kim | |

Tecentriq-Abraxane combination would be the first cancer immunotherapy for PD-L1-positive, metastatic triple-negative breast cancer (Image: Mayo Clinic)

5 Things to Know About Moderna's Proposed $500 Million IPO

Edward Kim | |

The proposed deal for this biotechnology unicorn would be the largest US IPO in the industry (Image: Moderna)

Alpine Immune Sciences Shows Positive Preclinical Data for Cancer Immunotherapy

Edward Kim | |

ALPN-202 combines dual checkpoint blockade action with T-cell costimulation

Mirum Pharmaceuticals Launches with $120 Million Series A and Phase 3-Ready Candidate for Rare Liver Diseases

Edward Kim | |

Financing led by NEA. Drug candidate licensed from Shire for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).

AVEO Oncology Shows Positive Phase 3 Results in Renal Cell Carcinoma

Edward Kim | |

Tivozanib showed 44% improvement in progression free survival and 26% reduction in risk of progression or death compared to sorafenib (Image: AVEO Pharmaceuticals)

Infinity Pharmaceuticals Expands Clinical Collaboration with Bristol-Myers Squibb to Urothelial Cancer

Edward Kim | |

Expansion of 2016 deal to evaluate Infinity PI3K-gamma inhibitor in combination with BMY's Opdivo (Image: Infinity Pharmaceuticals)

How Artificial Intelligence is Transforming Clinical Trial Recruitment

Visual Capitalist | |

Poor clinical trial recruitment can cause losses up to $8 million each day. How can health and pharma companies get better at finding the right patients?

Aquestive Gets FDA Approval for Oral Film Formulation of Clobazam for LGS Seizures

Edward Kim | |

First oral film formulation of clobazam, for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (Image: Aquestive Therapeutics)

Denali Therapeutics Signs Neurodegenerative and Inflammatory Disease Collaboration with Sanofi

Edward Kim | |

$125 million upfront + potentially over $1 billion in milestone payments to develop RIPK1 inhibitors (Image: Denali Therapeutics)

Emerging Growth

DirectView Holdings Inc

DirectView Holdings Inc designs and installs surveillance systems, digital video recording and services. The company through its subsidiaries operates within two divisions security and surveillance and video conferencing services.


Truth on Trial: Implications for Communicators – Part III

Truth on Trial” is just one of a series of forums put on by the Schar School of Policy & Government, whose panelists are among the most influential legal, communications,…

Learn more